167 related articles for article (PubMed ID: 36384314)
1. "N-Acetylcysteine for Obsessive-Compulsive and Related Disorders in Children and Adolescents: A Review".
Parli GM; Gales MA; Gales BJ
Ann Pharmacother; 2023 Jul; 57(7):847-854. PubMed ID: 36384314
[TBL] [Abstract][Full Text] [Related]
2. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.
Costa DLC; Diniz JB; Requena G; Joaquim MA; Pittenger C; Bloch MH; Miguel EC; Shavitt RG
J Clin Psychiatry; 2017 Jul; 78(7):e766-e773. PubMed ID: 28617566
[TBL] [Abstract][Full Text] [Related]
3. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis.
Issari Y; Jakubovski E; Bartley CA; Pittenger C; Bloch MH
J Clin Psychiatry; 2016 May; 77(5):e605-11. PubMed ID: 27249090
[TBL] [Abstract][Full Text] [Related]
4. N-Acetylcysteine for Pediatric Obsessive-Compulsive Disorder: A Small Pilot Study.
Li F; Welling MC; Johnson JA; Coughlin C; Mulqueen J; Jakubovski E; Coury S; Landeros-Weisenberger A; Bloch MH
J Child Adolesc Psychopharmacol; 2020 Feb; 30(1):32-37. PubMed ID: 31800306
[No Abstract] [Full Text] [Related]
5. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder.
Lafleur DL; Pittenger C; Kelmendi B; Gardner T; Wasylink S; Malison RT; Sanacora G; Krystal JH; Coric V
Psychopharmacology (Berl); 2006 Jan; 184(2):254-6. PubMed ID: 16374600
[TBL] [Abstract][Full Text] [Related]
6. N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial.
Paydary K; Akamaloo A; Ahmadipour A; Pishgar F; Emamzadehfard S; Akhondzadeh S
J Clin Pharm Ther; 2016 Apr; 41(2):214-9. PubMed ID: 26931055
[TBL] [Abstract][Full Text] [Related]
7. What Is the Added Benefit of Combining Cognitive Behavioral Therapy and Selective Serotonin Reuptake Inhibitors in Youth with Obsessive Compulsive Disorder? A Bayesian Hierarchical Modeling Meta-Analysis.
Mendez EM; Dahlsgaard KK; Hjelmgren JM; Mills JA; Suresh V; Strawn JR
J Child Adolesc Psychopharmacol; 2023 Aug; 33(6):203-211. PubMed ID: 37347947
[No Abstract] [Full Text] [Related]
8. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial.
Pediatric OCD Treatment Study (POTS) Team
JAMA; 2004 Oct; 292(16):1969-76. PubMed ID: 15507582
[TBL] [Abstract][Full Text] [Related]
9. Selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for anxiety, obsessive-compulsive, and stress disorders: A 3-level network meta-analysis.
Gosmann NP; Costa MA; Jaeger MB; Motta LS; Frozi J; Spanemberg L; Manfro GG; Cuijpers P; Pine DS; Salum GA
PLoS Med; 2021 Jun; 18(6):e1003664. PubMed ID: 34111122
[TBL] [Abstract][Full Text] [Related]
10. Distinct trajectories of long-term symptom severity in pediatric obsessive-compulsive disorder during and after stepped-care treatment.
Jensen S; Højgaard DRMA; Hybel KA; Mortensen EL; Skarphedinsson G; Melin K; Ivarsson T; Nissen JB; Weidle B; Valderhaug R; Torp NC; Dahl K; Compton S; Thomsen PH
J Child Psychol Psychiatry; 2020 Sep; 61(9):969-978. PubMed ID: 31736082
[TBL] [Abstract][Full Text] [Related]
11. Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors and Clomipramine in Pediatric Obsessive-Compulsive Disorder.
Varigonda AL; Jakubovski E; Bloch MH
J Am Acad Child Adolesc Psychiatry; 2016 Oct; 55(10):851-859.e2. PubMed ID: 27663940
[TBL] [Abstract][Full Text] [Related]
12. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Bloch MH; Landeros-Weisenberger A; Kelmendi B; Coric V; Bracken MB; Leckman JF
Mol Psychiatry; 2006 Jul; 11(7):622-32. PubMed ID: 16585942
[TBL] [Abstract][Full Text] [Related]
13. A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.
Albert U; Marazziti D; Di Salvo G; Solia F; Rosso G; Maina G
Curr Med Chem; 2018; 25(41):5647-5661. PubMed ID: 29278206
[TBL] [Abstract][Full Text] [Related]
14. N-Acetylcysteine in the Treatment of Pediatric Tourette Syndrome: Randomized, Double-Blind, Placebo-Controlled Add-On Trial.
Bloch MH; Panza KE; Yaffa A; Alvarenga PG; Jakubovski E; Mulqueen JM; Landeros-Weisenberger A; Leckman JF
J Child Adolesc Psychopharmacol; 2016 May; 26(4):327-34. PubMed ID: 27027204
[TBL] [Abstract][Full Text] [Related]
15. Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial.
March JS; Biederman J; Wolkow R; Safferman A; Mardekian J; Cook EH; Cutler NR; Dominguez R; Ferguson J; Muller B; Riesenberg R; Rosenthal M; Sallee FR; Wagner KD; Steiner H
JAMA; 1998 Nov; 280(20):1752-6. PubMed ID: 9842950
[TBL] [Abstract][Full Text] [Related]
16. N-Acetyl Cysteine (NAC) in the Treatment of Obsessive-Compulsive Disorder: A 16-Week, Double-Blind, Randomised, Placebo-Controlled Study.
Sarris J; Oliver G; Camfield DA; Dean OM; Dowling N; Smith DJ; Murphy J; Menon R; Berk M; Blair-West S; Ng CH
CNS Drugs; 2015 Sep; 29(9):801-9. PubMed ID: 26374743
[TBL] [Abstract][Full Text] [Related]
17. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
[TBL] [Abstract][Full Text] [Related]
18. Obsessive-Compulsive Disorder: Advances in Diagnosis and Treatment.
Hirschtritt ME; Bloch MH; Mathews CA
JAMA; 2017 Apr; 317(13):1358-1367. PubMed ID: 28384832
[TBL] [Abstract][Full Text] [Related]
19. A systematic review of the clinical effectiveness and cost-effectiveness of pharmacological and psychological interventions for the management of obsessive-compulsive disorder in children/adolescents and adults.
Skapinakis P; Caldwell D; Hollingworth W; Bryden P; Fineberg N; Salkovskis P; Welton N; Baxter H; Kessler D; Churchill R; Lewis G
Health Technol Assess; 2016 Jun; 20(43):1-392. PubMed ID: 27306503
[TBL] [Abstract][Full Text] [Related]
20. Oral N-acetylcysteine in the treatment of obsessive-compulsive disorder: A systematic review of the clinical evidence.
Couto JP; Moreira R
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Aug; 86():245-254. PubMed ID: 29908912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
